Contents

Search

gabapentin enacarbil (Horizant)

Indications: - restless legs syndrome (FDA-approved April 2011) - post-herpetic neuralgia [3] - partial seizure [3] Dosage: - 600 mg PO at 5 PM (QD) (extended-release) Pharmacokinetics: - better absorbed than gabapentin & longer-acting, but no evidence that it works better or is better tolerated than gabapentin [2] Adverse effects: - carries warning of all anticonvulsants of risk for suicidal ideation Mechanism of action: - precursor of gabapentin

Interactions

drug adverse effects of anticonvulsants monitor with anticonvulsants

General

gabapentin (Neurontin, Gralise)

References

  1. FDA NEWS RELEASE: April 7, 2011 FDA approves Horizant to treat restless legs syndrome http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250188.htm
  2. Prescriber's Letter 18(6): 2011 Restless Legs Syndrome (subscription needed) http://www.prescribersletter.com
  3. Deprecated Reference